Stereotaxis, Inc. (STXS)
NYSEAMERICAN: STXS · Real-Time Price · USD
2.200
-0.090 (-3.93%)
At close: Feb 21, 2025, 4:00 PM
2.180
-0.020 (-0.91%)
After-hours: Feb 21, 2025, 7:54 PM EST
Stereotaxis Revenue
Stereotaxis had revenue of $9.20M in the quarter ending September 30, 2024, with 17.91% growth. This brings the company's revenue in the last twelve months to $25.14M, down -14.79% year-over-year. In the year 2023, Stereotaxis had annual revenue of $26.77M, down -4.89%.
Revenue (ttm)
$25.14M
Revenue Growth
-14.79%
P/S Ratio
7.33
Revenue / Employee
$206,090
Employees
122
Market Cap
185.56M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 26.77M | -1.38M | -4.89% |
Dec 31, 2022 | 28.15M | -6.87M | -19.63% |
Dec 31, 2021 | 35.02M | 8.39M | 31.51% |
Dec 31, 2020 | 26.63M | -2.27M | -7.86% |
Dec 31, 2019 | 28.90M | -444.07K | -1.51% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
STXS News
- 8 days ago - Stock Market Sleeps On Stereotaxis MAGiC CE Mark - Seeking Alpha
- 18 days ago - Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 - GlobeNewsWire
- 23 days ago - Stereotaxis Announces First GenesisX Robotic System Order - GlobeNewsWire
- 26 days ago - Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter - GlobeNewsWire
- 5 weeks ago - Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology - GlobeNewsWire
- 2 months ago - Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA - GlobeNewsWire
- 2 months ago - Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems - GlobeNewsWire
- 2 months ago - Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025 - Seeking Alpha